Economic and Reimbursement Challenges in Aortic Aneurysm Treatment
The Aortic Aneurysm Market faces several economic and reimbursement challenges that influence patient access, hospital decision-making, and overall treatment adoption rates. While advancements in stent graft technology and minimally invasive techniques have improved outcomes, the associated costs remain a barrier for many healthcare systems—especially in low- and middle-income countries.
In developed nations, reimbursement policies often cover endovascular aneurysm repair (EVAR) and thoracic EVAR (TEVAR), but the extent of coverage varies. High device costs, coupled with expenses for pre-procedure imaging, post-procedure monitoring, and potential reinterventions, can place a strain on public health budgets. Private insurance coverage helps alleviate this burden in some markets, but gaps still exist, particularly for newer, premium devices not yet included in standard reimbursement schedules.
Economic challenges also extend to hospitals, which must balance the clinical benefits of adopting advanced technology with the financial realities of procurement and training. Negotiating with device manufacturers for volume-based pricing is becoming more common, especially among large hospital networks.
In emerging economies, limited reimbursement and out-of-pocket payment requirements hinder access to advanced treatments, resulting in lower adoption rates. Addressing these disparities will require coordinated efforts between policymakers, insurers, and medical device companies to create sustainable funding and pricing models that enable broader patient access.